Jinhai Medical Technology Limited

SEHK:2921 Stock Report

Market Cap: HK$8.5b

Jinhai Medical Technology Past Earnings Performance

Past criteria checks 0/6

Jinhai Medical Technology's earnings have been declining at an average annual rate of -58.7%, while the Professional Services industry saw earnings growing at 2.6% annually. Revenues have been declining at an average rate of 2.9% per year.

Key information

-58.7%

Earnings growth rate

-58.0%

EPS growth rate

Professional Services Industry Growth23.9%
Revenue growth rate-2.9%
Return on equity-28.3%
Net Margin-17.0%
Last Earnings Update30 Jun 2024

Recent past performance updates

No updates

Recent updates

No updates

Revenue & Expenses Breakdown

How Jinhai Medical Technology makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SEHK:2921 Revenue, expenses and earnings (SGD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2460-10260
31 Mar 2453-7210
31 Dec 2346-3170
30 Sep 2333-2140
30 Jun 23200110
31 Mar 23210100
31 Dec 22220100
30 Sep 22250100
30 Jun 2227090
31 Mar 2224090
31 Dec 2122090
30 Sep 2120090
30 Jun 2118190
31 Mar 21201100
31 Dec 20221110
30 Sep 20311120
30 Jun 20400120
31 Mar 20460130
31 Dec 1952-1130
30 Sep 1951-1130
30 Jun 1951-2130
31 Mar 1949-3130
31 Dec 1847-4130
30 Sep 1846-2110
30 Jun 1844-190
31 Mar 1844180
31 Dec 1744270
31 Dec 1645780
31 Dec 1546680
31 Dec 1445490

Quality Earnings: 2921 is currently unprofitable.

Growing Profit Margin: 2921 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 2921 is unprofitable, and losses have increased over the past 5 years at a rate of 58.7% per year.

Accelerating Growth: Unable to compare 2921's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2921 is unprofitable, making it difficult to compare its past year earnings growth to the Professional Services industry (33.8%).


Return on Equity

High ROE: 2921 has a negative Return on Equity (-28.25%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 05:21
End of Day Share Price 2024/12/19 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jinhai Medical Technology Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution